Loading Valiant Laboratories…
| ₹ Cr | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 |
|---|---|---|---|---|---|
| Revenue | 115 | 92 | 52 | 46 | 47 |
| Operating profit | 26 | 2 | -3 | -0 | 2 |
| Operating margin | 22.9% | 2.1% | -5.6% | -1.0% | 4.0% |
| Net profit | 21 | 2 | -7 | 0 | 2 |
| Net margin | 18.3% | 1.9% | -13.5% | 0.4% | 3.9% |
| EPS (₹) | 3.89 | 0.32 | -1.44 | 0.04 | 0.42 |
Quarters are labelled by period end.
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Revenue | 237 | 133 | 182 | 334 |
| Operating profit | 1 | -4 | -10 | 34 |
| Operating margin | 0.2% | -2.6% | -5.7% | 10.1% |
| Net profit | -3 | -2 | 0 | 29 |
| Net margin | -1.4% | -1.7% | 0.2% | 8.7% |
| EPS (₹) | -0.65 | -0.47 | 0.12 | 6.19 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Total assets | 464 | 401 | 343 | 213 |
| Total liabilities | 153 | 167 | 106 | 112 |
| Shareholders’ equity | 311 | 234 | 237 | 100 |
| Total debt | 46 | 122 | 77 | 60 |
| Cash & equivalents | 4 | 5 | 12 | 1 |
| Debt / equity | 0.15 | 0.52 | 0.32 | 0.60 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Operating cash flow | -10 | 1 | 2 | 56 |
| Capital expenditure | -34 | -114 | -46 | -38 |
| Free cash flow | -45 | -113 | -44 | 18 |
| ₹ Cr | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 |
|---|---|---|---|---|
| Return on equity | -1.1% | -0.9% | 0.1% | 28.9% |
| Return on assets | -0.7% | -0.5% | 0.1% | 13.6% |
| Net margin | -1.4% | -1.7% | 0.2% | 8.7% |
Source: Yahoo Finance. Figures in ₹ crore unless stated.
No analyst data available for VALIANTLAB. Finnhub coverage is limited for some India-listed stocks.